OBR Daily Commentary

forumImage

Lethal Prostate Cancer Treatment May Benefit from Combination Immunotherapy

(Johns Hopkins) June 25, 2018 - Researchers at the Johns Hopkins Kimmel Cancer Center and the Bloomberg~Kimmel Institute for Cancer Immunotherapy (BKI) released a study investigating the use of combination checkpoint immunotherapy in the treatment of a lethal form of advanced prostate cancer. The study suggested a genetic subset of prostate cancer may benefit from this form of immunotherapy.

Read Article arrow

Tomasz M. Beer, MD (Posted: June 25, 2018)

quotesSeveral interesting things about this study. Combination checkpoint inhibition has proven useful in other cancers, but is new to prostate cancer. Patient enrollment using the AR-V7 assays to select highest risk patients is novel and represents the first such study. Finally, the links between DNA repair defects and response extends prior findings and provides new evidence that this relationship may extend beyond microsatellite instability. This regimen is not ready for clinical use, but is of interest for further study.quotes

Add Comment 1 Comment
forumImage

Top-Five National Payer Issues Positive Coverage Decision for Myriad's Prolaris® Test for Prostate Cancer

(Myriad Genetics) June 21, 2018 - Decision follows recently updated medical guidelines for prostate cancer.

Read Article arrow

Tomasz M. Beer, MD, FACP (Posted: June 21, 2018)

quotesIncreasing availability of molecular tests to risk stratify patients is encouraging. With over-treatment of low risk disease a core challenge in prostate cancer, the use of such tests to increase the proportion of men opting for observation would mean progress. For this to happen, urologists, oncologists, and patients will need to be comfortable trusting the results and acting on them. The tests should only be used when the clinician is willing to act on the result.quotes

Add Comment 1 Comment
forumImage

OncBioMune to Commence Phase 2 Trial of ProscaVax for Early Stage Prostate Cancer Patients

(NASDAQ) June 20, 2018 - To the Company's knowledge, the trial of ProscaVax is the first ever worldwide for a prostate cancer vaccine technology addressing the active surveillance patient population.

Read Article arrow

Tomasz M. Beer, MD, FACP (Posted: June 20, 2018)

quotesWith about half of the patients who initially choose active surveillance progressing to definitive therapy, there is an opportunity for low toxicity interventions to reduce the need for more aggressive therapies. While sipuleucel-T was successfully developed for prostate cancer, a number of other vaccine based immunotherapy strategies have not succeeded. This is the first one being deployed in the active surveillance setting. quotes

Add Comment 1 Comment

Meet the Editorial Board

Prostate Cancer
member photo
Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...